Nasal spray could ease public speaking panic in social anxiety
NCT ID NCT06358651
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tests an experimental nasal spray called fasedienol for quickly reducing anxiety during a public speaking challenge in adults with social anxiety disorder. About 238 participants will receive either the spray or a placebo and rate their distress. The goal is to see if the spray provides fast, safe relief without long-term medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOCIAL ANXIETY DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Vistagen Clinical Site
Phoenix, Arizona, 85012, United States
-
Vistagen Clinical Site
Fayetteville, Arkansas, 72703, United States
-
Vistagen Clinical Site
Little Rock, Arkansas, 72211, United States
-
Vistagen Clinical Site
Lafayette, California, 94549, United States
-
Vistagen Clinical Site
Oceanside, California, 92056, United States
-
Vistagen Clinical Site
Sherman Oaks, California, 91403, United States
-
Vistagen Clinical Site
Denver, Colorado, 80209, United States
-
Vistagen Clinical Site
Cromwell, Connecticut, 06416, United States
-
Vistagen Clinical Site
Jacksonville, Florida, 32256, United States
-
Vistagen Clinical Site
Lakeland, Florida, 33803, United States
-
Vistagen Clinical Site
Orlando, Florida, 32801, United States
-
Vistagen Clinical Site
West Palm Beach, Florida, 33407, United States
-
Vistagen Clinical Site
Chicago, Illinois, 60612, United States
-
Vistagen Clinical Site
Overland Park, Kansas, 66210, United States
-
Vistagen Clinical Site
Baltimore, Maryland, 21208, United States
-
Vistagen Clinical Site
Boston, Massachusetts, 02131, United States
-
Vistagen Clinical Site
Saint Charles, Missouri, 63304, United States
-
Vistagen Clinical Site
Las Vegas, Nevada, 89119, United States
-
Vistagen Clinical Site
New York, New York, 10128, United States
-
Vistagen Clinical Site
Media, Pennsylvania, 19063, United States
-
Vistagen Clinical Site
Memphis, Tennessee, 38119, United States
-
Vistagen Clinical Site
Fort Worth, Texas, 76104, United States
-
Vistagen Clinical Site
Draper, Utah, 84020, United States
-
Vistagen Clinical Site
Everett, Washington, 98201, United States
Conditions
Explore the condition pages connected to this study.